News — CHICAGO – While CAR T cell therapy has revolutionized treatment for many blood cancers, including (NHL), many patients who receive CAR T cell therapy do not experience a long-term remission. For those whose cancers return or become resistant after CAR T cell therapy, the prognosis is poor, with few options left.
A new “armored” form of CAR T cell therapy, developed by , the Richard W. Vague Professor in Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania, may be able to help these patients. According to the results of a , presented today at the (), the new CAR T was safe, and had a three-month overall response rate of 80 percent in 20 patients with NHL whose cancers were relapsed or had stopped responding to treatment after receiving a commercially available CAR T cell therapy.
“By the time we treat someone with commercially available FDA-approved CAR T cell therapies, they’ve already tried at least one other treatment that either didn’t work at all or their lymphoma relapsed, and they’re very hopeful that CAR T cell therapy—which has made such a difference for so many—will work for them too,” said , an associate professor of Hematology-Oncology, who led the clinical trial at Penn Medicine’s . “If the standard of care CAR T cell therapy doesn’t work for them, it’s incredibly disappointing. While we still have more follow-up to do, it’s gratifying to see so many patients with lymphoma responding to this novel CAR T cell product developed here at Penn.”
The first-in-human study evaluated huCART19-IL18, an anti-CD19 CAR that was further modified to secrete the pro-inflammatory cytokine, interleukin 18 (IL 18), based on preclinical studies that showed it could enhance CAR T activity.
“We’ve likened this CAR T to an armored truck or tank because the release of IL 18 further protects the CAR T cells and promotes their ability to attack the cancer cells,” said June, whose pioneering research led to the .
The production of huCART19-IL18 also uses a process, developed by Penn’s , that shortens the manufacturing time for the CAR T cells to three days. For patients with aggressive, fast-growing cancers, this means being able to begin CAR T cell therapy quicker than is currently possible with standard manufacturing times of nine to 14 days. A found the shortened manufacturing time also may enhance the potency of the T cells.
The addition of IL 18 did not result in any new or unexpected safety concerns beyond the known side effects of CAR T cell therapy, including cytokine release syndrome (CRS) and neurotoxicity, which were managed successfully. As patient follow-up continues, the median overall survival after treatment has not been determined yet, with some of the earliest patients treated now in remission for two years or more. These results represent an update from .
to learn more about open cancer clinical trials at Penn Medicine or call 1-855-216-0098 to speak to a clinical trial navigator.
Svoboda will present the study in an Oral Abstract Session on Saturday, June 1 at 3 p.m. CT in S100bc.
###
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the and Penn’s , founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.
RSS